Regulatory Q&A Forum
Ask questions, share knowledge, and get help from the regulatory community
Can a single provider act as both a GDPR Article 27 Representative and an Authorised Representative under the EU AI Act? For non-EU companies placing products or services on the European market, appo...
As non-EU manufacturers navigate various European Union regulations, the requirement to appoint a local representative is a common theme, seen in frameworks like the Medical Device Regulation (MDR). T...
For non-EU medical device manufacturers, establishing a presence in the European market involves navigating multiple, distinct regulatory frameworks. Beyond appointing an EU Authorized Representative ...
For non-EU medical device manufacturers, navigating the European market requires appointing an EU Authorized Representative (AR). However, the regulatory landscape is expanding beyond product-specific...
For a foreign cosmetic facility navigating the mandatory FDA registration and product listing requirements, what is a comprehensive framework for selecting a qualified U.S. Agent? Beyond the basic sta...
With the implementation of new mandatory requirements for cosmetic facility registration and product listing, foreign manufacturers must appoint a U.S. Agent to interact with the FDA. Beyond simply fu...
With the implementation of the Modernization of Cosmetics Regulation Act (MoCRA), foreign cosmetic establishments must designate a U.S. Agent to serve as the primary point of contact for the FDA. As c...
As non-EU cosmetics brands navigate evolving EU regulations and approach key compliance deadlines, the selection of an EU Responsible Person (RP) extends far beyond a simple administrative requirement...
Given the significant EU cosmetic regulatory updates anticipated through 2026, how should a non-EU brand structure its selection process for a new Responsible Person (RP) to ensure they are not just a...
Given the heightened responsibilities and joint liability assigned to the EU Authorised Representative (AR) under the Medical Device Regulation (EU) 2017/745 (MDR), how can a non-EU medical device man...
When planning for a 2026 submission of a novel in vitro diagnostic (IVD) device, particularly one that may not have a clear predicate or could fall into a classification requiring special controls, wh...
For an AI company based outside the EU that processes the personal data of EU residents, appointing a GDPR Article 27 representative is a mandatory step. However, given the complexity and scale of dat...
For foreign medical device establishments planning to enter the U.S. market, appointing a U.S. Agent is a mandatory step for FDA registration. Beyond simply fulfilling this requirement, what key facto...
With the introduction of the EU Carbon Border Adjustment Mechanism (CBAM), non-EU medical device manufacturers, who are already required to appoint an Authorized Representative (AR) under the Medical ...
Given the new compliance landscape created by the EU's Packaging and Packaging Waste Regulation (PPWR), how can non-EU manufacturers effectively evaluate the factors that influence the scope and cost ...
With the implementation of the EU's Packaging and Packaging Waste Regulation (PPWR), many non-EU economic operators will need to appoint an Authorized Representative (AR). While a primary concern is t...
With the implementation of the Modernization of Cosmetics Regulation Act (MoCRA), what are the specific, practical steps and strategic considerations for a foreign cosmetic product facility when appoi...
Given the new FDA requirements for cosmetic facility registration and product listing, foreign establishments must now appoint a U.S. Agent. While the cost of this service is a common question, the an...
With the implementation of the Modernization of Cosmetics Regulation Act of 2022 (MoCRA) and the launch of the new electronic submission portal for cosmetic facility registration and product listing, ...
When a medical device manufacturer is preparing for compliance with multiple, distinct regulatory frameworks, selecting the right external expertise is critical. For companies subject to the EU Medica...